NASDAQ:CMMB Chemomab Therapeutics (CMMB) Stock Forecast, Price & News $1.70 -0.03 (-1.73%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$1.63▼$1.7650-Day Range$1.42▼$1.8452-Week Range$1.38▼$5.35Volume17,892 shsAverage Volume524,875 shsMarket Capitalization$18.79 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Chemomab Therapeutics MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside311.8% Upside$7.00 Price TargetShort InterestHealthy4.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.70) to ($1.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector766th out of 985 stocksPharmaceutical Preparations Industry381st out of 483 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Chemomab Therapeutics has a forecasted upside of 311.8% from its current price of $1.70.Amount of Analyst CoverageChemomab Therapeutics has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.80% of the float of Chemomab Therapeutics has been sold short.Short Interest Ratio / Days to CoverChemomab Therapeutics has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Chemomab Therapeutics has recently decreased by 7.32%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldChemomab Therapeutics does not currently pay a dividend.Dividend GrowthChemomab Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMMB. Previous Next 2.4 News and Social Media Coverage News SentimentChemomab Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Chemomab Therapeutics this week, compared to 1 article on an average week.Search Interest3 people have searched for CMMB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.80% of the stock of Chemomab Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Chemomab Therapeutics are expected to grow in the coming year, from ($1.70) to ($1.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chemomab Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chemomab Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChemomab Therapeutics has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Chemomab Therapeutics (NASDAQ:CMMB) StockChemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.Read More Receive CMMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CMMB Stock News HeadlinesJune 5, 2023 | markets.businessinsider.comHemomab Therapeutics Reappoints Adi Mor As CEO; Sigal Fattal Reassumes Role Of CFOJune 5, 2023 | msn.comChemomab Therapeutics announces key management changesJune 6, 2023 | Altimetry (Ad)Biden's latest bailout--terrible for America?And a consultant for the Dept. of Defense (Joel Litman) says this is all leading to an event in the next 20 months that could help some get vastly wealthier… but also make it harder than ever to hang onto any money you make.This might be the most important development affecting you and your money over the next few years—June 5, 2023 | finance.yahoo.comChemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate UpdateJune 2, 2023 | finance.yahoo.comPatient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic SclerosisMay 29, 2023 | americanbankingnews.comChemomab Therapeutics (NASDAQ:CMMB) versus Theratechnologies (OTCMKTS:THERF) Critical ComparisonMay 24, 2023 | finance.yahoo.comChemomab Therapeutics to Participate in Upcoming Scientific ConferencesMay 16, 2023 | finance.yahoo.comChemomab Therapeutics Ltd. (NASDAQ:CMMB) Q1 2023 Earnings Call TranscriptJune 6, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 11, 2023 | finanznachrichten.deChemomab Therapeutics, Ltd.: Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate UpdateMay 11, 2023 | finance.yahoo.comChemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate UpdateMay 10, 2023 | americanbankingnews.comChemomab Therapeutics (CMMB) Set to Announce Quarterly Earnings on ThursdayApril 26, 2023 | finance.yahoo.comChemomab Therapeutics to Present at 2023 Aegis Virtual ConferenceApril 21, 2023 | americanbankingnews.comOppenheimer Weighs in on Chemomab Therapeutics Ltd.'s Q1 2024 Earnings (NASDAQ:CMMB)April 19, 2023 | msn.comOppenheimer Maintains Chemomab Therapeutics (CMMB) Outperform RecommendationApril 18, 2023 | americanbankingnews.comChemomab Therapeutics (NASDAQ:CMMB) PT Lowered to $7.00April 12, 2023 | finance.yahoo.comChemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate UpdateMarch 31, 2023 | benzinga.comChemomab Therapeutics Stock (NASDAQ:CMMB), Guidance and ForecastMarch 30, 2023 | msn.comA Preview Of Chemomab Therapeutics's EarningsMarch 30, 2023 | americanbankingnews.comChemomab Therapeutics (CMMB) Set to Announce Earnings on FridayMarch 29, 2023 | finance.yahoo.comChemomab Therapeutics to Provide a Corporate Update on April 17, 2023March 17, 2023 | finance.yahoo.comChemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business UpdateMarch 6, 2023 | finance.yahoo.comChemomab to Present at the Oppenheimer 33rd Annual Healthcare ConferenceFebruary 25, 2023 | marketwatch.comChemomab Therapeutics Shares Fall 16%, Hitting 52-Week LowFebruary 23, 2023 | morningstar.comChemomab Therapeutics stock soars after FDA clears IND for SSc treatmentFebruary 23, 2023 | finance.yahoo.comIs Chemomab Therapeutics (NASDAQ:CMMB) In A Good Position To Invest In Growth?February 21, 2023 | marketwatch.comChemomab Therapeutics Climbs After FDA Clears Application for SSc TreatmentSee More Headlines CMMB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMMB Company Calendar Last Earnings3/20/2023Today6/06/2023Next Earnings (Estimated)8/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CMMB CUSIPN/A CIK1534248 Webwww.chemomab.com Phone972-77-331-0156FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+311.8%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($2.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-77.93% Return on Assets-67.79% Debt Debt-to-Equity RatioN/A Current Ratio4.83 Quick Ratio4.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.11 per share Price / Book0.55Miscellaneous Outstanding Shares11,050,000Free Float9,734,000Market Cap$18.79 million OptionableNot Optionable Beta0.35 Key ExecutivesDr. Dale R. Pfost Ph.D. (Age 65)Chairman & CEO Comp: $192kDr. Adi Mor George Ph.D. (Age 40)Co-Founder, Chief Scientific Officer & Exec. Director Comp: $480kMr. Donald R. Marvin MBA (Age 69)CFO, Exec. VP & COO Comp: $94kBarbara LindheimConsulting VP of Investor & PR, Strategic CommunicationsMr. Mitchell Lawrence Jones M.D.Ph.D., VP of Corp. Devel. & StrategyDr. Matthew Frankel M.B.A.M.D., Chief Medical Officer & VP of Drug Devel.More ExecutivesKey CompetitorsOncternal TherapeuticsNASDAQ:ONCTBionomicsNASDAQ:BNOXNightHawk BiosciencesNYSE:NHWKHumanigenNASDAQ:HGENTonix PharmaceuticalsNASDAQ:TNXPView All CompetitorsInsiders & InstitutionsTwo Sigma Investments LPBought 30,263 shares on 5/15/2023Ownership: 0.274%Boothbay Fund Management LLCSold 25,079 shares on 5/15/2023Ownership: 0.240%Israel Gp Ltd. OrbimedSold 336,900 sharesTotal: $1.21 M ($3.58/share)George Adi MorSold 324,775 sharesTotal: $675,532.00 ($2.08/share)Neil Harris CohenSold 2,409 sharesTotal: $4,818.00 ($2.00/share)View All Insider TransactionsView All Institutional Transactions CMMB Stock - Frequently Asked Questions What is Chemomab Therapeutics' stock price forecast for 2023? 0 analysts have issued 12 month price objectives for Chemomab Therapeutics' stock. Their CMMB share price forecasts range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next year. This suggests a possible upside of 311.8% from the stock's current price. View analysts price targets for CMMB or view top-rated stocks among Wall Street analysts. How have CMMB shares performed in 2023? Chemomab Therapeutics' stock was trading at $3.20 at the beginning of 2023. Since then, CMMB shares have decreased by 46.9% and is now trading at $1.70. View the best growth stocks for 2023 here. Are investors shorting Chemomab Therapeutics? Chemomab Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 422,900 shares, a decrease of 7.3% from the April 30th total of 456,300 shares. Based on an average trading volume of 74,000 shares, the days-to-cover ratio is presently 5.7 days. Currently, 4.8% of the shares of the stock are sold short. View Chemomab Therapeutics' Short Interest. When is Chemomab Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our CMMB earnings forecast. How were Chemomab Therapeutics' earnings last quarter? Chemomab Therapeutics Ltd. (NASDAQ:CMMB) released its quarterly earnings data on Monday, March, 20th. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.80) by $0.08. What is Chemomab Therapeutics' stock symbol? Chemomab Therapeutics trades on the NASDAQ under the ticker symbol "CMMB." Who are Chemomab Therapeutics' major shareholders? Chemomab Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Two Sigma Investments LP (0.27%) and Boothbay Fund Management LLC (0.24%). Insiders that own company stock include Dale R Pfost, Donald Marvin, George Adi Mor, Israel Gp Ltd Orbimed, Joel Michael Maryles and Neil Harris Cohen. View institutional ownership trends. How do I buy shares of Chemomab Therapeutics? Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Chemomab Therapeutics' stock price today? One share of CMMB stock can currently be purchased for approximately $1.70. How much money does Chemomab Therapeutics make? Chemomab Therapeutics (NASDAQ:CMMB) has a market capitalization of $18.79 million. The company earns $-27,650,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. How can I contact Chemomab Therapeutics? Chemomab Therapeutics' mailing address is KIRYAT ATIDIM BUILDING 7, TEL AVIV L3, 6158002. The official website for the company is www.chemomab.com. The company can be reached via phone at 972-77-331-0156 or via email at arr@lifesciadvisors.com. This page (NASDAQ:CMMB) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.